About this episode
The FDA has granted priority review to gedatolisib, a first-in-class PI3K/mTOR inhibitor for HR-positive, HER2-negative, PIK3CA wild-type advanced breast cancer. In this episode, we explain why this fast-tracked review is such a major milestone—and how it could change treatment options for patients worldwide.You’ll learn:What FDA priority review means and why it matters for cancer patientsHow gedatolisib works and why it’s different from existing breast cancer therapiesWhy HR+/HER2–, PIK3CA wild-type breast cancer has been an unmet treatment needKey results from the Phase 3 VIKTORIA-1 trial, including progression-free survival and response ratesHow gedatolisib compares to fulvestrant alone after CDK4/6 inhibitor failureWhat the drug’s safety and tolerability profile looks like in real patientsHow FDA approval could impact global care, including access to targeted therapy in MalaysiaWith a PDUFA decision date set for July 17, 2026, this episode breaks down what breast cancer patients and caregivers should know now—and why gedatolisib could become a new standard of care.Blog Link: FDA Grants Priority Review to Gedatolisib: What It Means for Breast Cancer PatientsSend us Fan MailThank you for listening to The Onco Life Podcast, your trusted source for expert cancer information and patient-centered education.Author: Dr. CHRISTINA NG VAN TZE📍 Visit us at oncolifecentre.com 📞 Call: +603-2242-2620 📧 Book a consultation or ask a question — we're here to support your journey.
